Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

ConclusionsAmong patients with persistent PTH, erenumab resulted in a lower frequency of moderate to severe headache days in this 12-week open-label trial. In addition, erenumab was well-tolerated as discontinuations due to adverse events were low. Placebo-controlled randomized clinical trials are needed to adequately evaluate the efficacy and safety of erenumab in patients with  persistent PTH.Trial registrationClinicalTrials.Gov,NCT03974360. Registered on April 17, 2019 - Retrospectively registered
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research